Comparative Analysis, page-8

I guess depends on the share price at the time. I would argue that the current share price is already heavily discounted. the comparative analysis support this.

Given there are 4 x Phase 1b trials in progress, multiple data read outs, FDA designations for orphan drug/breakthrough/ RMAT very real possibilities. Also the company has made no secret that it is already speaking to big pharma, with negotiations expected to progress further once we get critical mass on the trials (eg. 6+ patients enrolled in CDH17 - currently have at least 3 enrolled and a "line out the door" according to the CEO)